ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

COG Cambridge Cognition Holdings Plc

45.00
0.50 (1.12%)
17 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cambridge Cognition Holdings Plc LSE:COG London Ordinary Share GB00B8DV9647 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 1.12% 45.00 44.00 46.00 45.00 44.50 44.50 155,779 14:38:17
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 12.61M -409k -0.0117 -38.46 15.68M

Cambridge Cognition Holdings PLC Trading Update

30/01/2024 7:00am

RNS Regulatory News


RNS Number : 2725B
Cambridge Cognition Holdings PLC
30 January 2024
 

30 January 2024

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Trading Update

 

Return to profitability in H2; above expectation bottom line performance

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce a trading update for the year ended 31 December 2023.

 

Key (Unaudited) highlights:

·         Revenue growth of 7% to £13.5 million (2022: £12.6 million)

·         Adjusted operating profit of £0.9 million in H2 (2023 H1: loss of £2.1 million)

·         Adjusted operating loss of £1.2 million for the year (2022: £0.1 million profit), better than market expectations

Full year adjusted operating loss reflects the impact of business acquisitions and difficult H1 trading conditions

·         Cash balance of £3.2 million at 31 December 2023 (31 December 2022: £8.3 million)

 

2023 was a year of significant progress for the Company operationally following the acquisitions of eClinicalHealth Limited ("Clinpal") at the end of 2022 and Winterlight Labs Inc ("Winterlight") at the beginning of 2023.  Both of these acquisitions have now been fully integrated into the Group and annualised cost savings in excess of £1.5 million have been realised. Leveraging the unique capabilities of the acquired businesses, the Company recently launched combined product offerings during the year including AQUA, an Automated Quality Assurance solution derived from the Winterlight platform, which strengthens the Company's product portfolio and provides additional cross-selling opportunities. This contributed to a major contract win in October 2023 for a sizeable later stage clinical trial valued at £1 million.

 

With revenue increasing 7% over the prior year to £13.5 million and following the comprehensive integration and re-organisation mid-year, the Company made an adjusted operating profit of £0.9 million in H2, improving the adjusted operating loss from £2.1 million in H1 to £1.2 million at the end of the year.  The H2 adjusted operating profit was better than expected due to robust cost control. The contracted order book remained healthy at the end of 2023 at £17.2 million (£17.6 million at 31 December 2022), with at least £8.0 million of the current contracted order book expected to be recognised as revenue in 2024, subject to customer trial schedules.

 

Outlook

 

There has been considerable M&A activity by large pharmaceutical companies in the central nervous system ("CNS") drug development sector recently and, together with an improving global economic outlook, that is expected to prompt further investment in CNS clinical trials. The Company is focused on capitalising on this market opportunity, growing the order book and maximising the benefits of the recent acquisitions to drive sustainable profitable growth. 

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, commented:


"Despite challenging market conditions during 2023, the Company has strengthened its technology platforms and commercial offering and is positioned to capitalise on the anticipated growth in the CNS drug development market. We continue to focus on delivering profitable growth and driving success over the medium-term."

 

 

The Company will announce its preliminary results for the year ended 31 December 2023 in April 2024.

 

 

The information communicated in this announcement contains inside information for the purposes of the UK Market Abuse Regulations.

 

 

Enquiries:

 

Cambridge Cognition Holdings plc 

Matthew Stork, Chief Executive Officer 

Stephen Symonds, Chief Financial Officer 

Tel: 012 2381 0700 

press@camcog.com 

 

Panmure Gordon (UK) Limited (NOMAD and Joint Broker) 

Freddy Crossley / Emma Earl  

Rupert Dearden 

 

Tel: 020 7886 2968 

(Corporate Finance) 

(Corporate Broking) 

 

Dowgate Capital Limited (Joint Broker) 

David Poutney / James Serjeant 

 

Tel: 020 3903 7715 

 

 

Hudson Sandler (Financial PR and IR) 

Dan de Belder / Hattie Dreyfus 

 

Tel: 020 7796 4133 

cog@hudsonsandler.com

 


 

 

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFIDLEIAFIS

1 Year Cambridge Cognition Chart

1 Year Cambridge Cognition Chart

1 Month Cambridge Cognition Chart

1 Month Cambridge Cognition Chart

Your Recent History

Delayed Upgrade Clock